{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:17:12Z","timestamp":1780550232110,"version":"3.54.1"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2003,1,1]],"date-time":"2003-01-01T00:00:00Z","timestamp":1041379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The in vitro susceptibilities to garenoxacin (BMS-284756), an investigational des-fluoroquinolone, and eight other agents were determined for 63\n            <jats:italic>Mycoplasma pneumoniae<\/jats:italic>\n            , 45\n            <jats:italic>Mycoplasma hominis<\/jats:italic>\n            , 15\n            <jats:italic>Mycoplasma fermentans<\/jats:italic>\n            , and 68\n            <jats:italic>Ureaplasma<\/jats:italic>\n            sp. isolates. Garenoxacin was the most active quinolone, inhibiting all isolates at \u22641 \u03bcg\/ml. The garenoxacin MIC at which 90% of isolates are inhibited (MIC\n            <jats:sub>90<\/jats:sub>\n            s; \u22640.008 \u03bcg\/ml) was at least 4-fold less than those of moxifloxacin and clindamycin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin for\n            <jats:italic>M. pneumoniae<\/jats:italic>\n            . For\n            <jats:italic>M. hominis<\/jats:italic>\n            , the garenoxacin MIC\n            <jats:sub>90<\/jats:sub>\n            (\u22640.008 \u03bcg\/ml) was 4-fold less than those of clindamycin and moxifloxacin, 8-fold less than that of sparfloxacin, and 64-fold less than those of levofloxacin and ciprofloxacin. All 15\n            <jats:italic>M. fermentans<\/jats:italic>\n            isolates were inhibited by garenoxacin at concentrations \u22640.008 \u03bcg\/ml, making it the most active drug tested against this organism. For\n            <jats:italic>Ureaplasma<\/jats:italic>\n            spp., the garenoxacin MIC\n            <jats:sub>90<\/jats:sub>\n            (0.25 \u03bcg\/ml) was equivalent to those of moxifloxacin and doxycycline, 4-fold less than those of levofloxacin and sparfloxacin, 8-fold less than that of azithromycin, and 32-fold less than that of ciprofloxacin. Garenoxacin and the other fluoroquinolones tested were demonstrated to have bactericidal activities against\n            <jats:italic>M. pneumoniae<\/jats:italic>\n            and\n            <jats:italic>M. hominis<\/jats:italic>\n            by measurement of minimal bactericidal activities and by time-kill studies. Further study of garenoxacin is required, as it has great potential for use in the treatment of infections due to mycoplasmas and ureaplasmas.\n          <\/jats:p>","DOI":"10.1128\/aac.47.1.161-165.2003","type":"journal-article","created":{"date-parts":[[2002,12,24]],"date-time":"2002-12-24T04:39:08Z","timestamp":1040704748000},"page":"161-165","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":71,"title":["In Vitro Susceptibilities to and Bactericidal Activities of Garenoxacin (BMS-284756) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas"],"prefix":"10.1128","volume":"47","author":[{"given":"Ken B.","family":"Waites","sequence":"first","affiliation":[{"name":"Departments of Pathology"},{"name":"Microbiology, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Crabb","sequence":"additional","affiliation":[{"name":"Microbiology, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bing","sequence":"additional","affiliation":[{"name":"Microbiology, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn B.","family":"Duffy","sequence":"additional","affiliation":[{"name":"Microbiology, University of Alabama at Birmingham, Birmingham, Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.3.703"},{"key":"e_1_3_2_3_2","first-page":"711","volume":"43","year":"1999","unstructured":"B\u00e9b\u00e9ar, C. M., H. Renaudin, T. Shaeverbeke, F. LeBlanc, and C. B\u00e9b\u00e9ar. 1999. In vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas. J. Antimicrob. Chemother.43:711-714.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1980-1982.2000"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2557-2560.2000"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jac\/40.2.308","volume":"40","year":"1997","unstructured":"Cohen, M. A., and M. D. Huband. 1997. In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs. J. Antimicrob. Chemother.40:308-309.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0732-8893(01)00285-1","volume":"41","year":"2001","unstructured":"Dubois, J., and C. St-Pierre. 2001. In vitro susceptibility of BMS-284756 against Legionella species. Diagn. Microbiol. Infect. Dis.41:79-82.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_8_2","first-page":"29","volume":"45","year":"2000","unstructured":"Duffy, L. B., D. Crabb, K. Searcey, and M. J. Kempf. 2000. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp. J. Antimicrob. Chemother.45(Suppl. S1):29-33.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.12.3351-3356.2000"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1908-1910.2001"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/jac\/45.3.367","volume":"45","year":"2000","unstructured":"Hannan, P. C. T., and G. Woodnutt. 2000. In vitro activity of gemifloxacin (SB 265805;LB20304a) against human mycoplasmas. J. Antimicrob. Chemother.45:367-369.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.4.738"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.1.103"},{"key":"e_1_3_2_14_2","first-page":"98","volume":"20","year":"1990","unstructured":"Kenny, G. E., and F. D. Cartwright. 1990. Mycoplasmacidal activity of quinolones on genital mycoplasmas. Zentbl. Bakteriol. Parasitenkd. Infektkrankh. Hyg. Abt. 1 Orig. Suppl.20:98-102.","journal-title":"Zentbl. Bakteriol. Parasitenkd. Infektkrankh. Hyg. Abt. 1 Orig. Suppl."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.7.1515"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.3.587"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.4.1048"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.9.2604-2608.2001"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.2.517-518.2002"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.251-254.2002"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jac\/37.suppl_A.19","volume":"37","year":"1996","unstructured":"Perea, E. J., J. Aznar, M. C. Garcia-Iglesias, and A. Pascual. 1996. Comparative in-vitro activity of sparfloxacin against genital pathogens. J. Antimicrob. Chemother.37(Suppl. A):19-25.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.312-315.2001"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jac\/43.suppl_3.33","volume":"43","year":"1999","unstructured":"Ullmann, U., S. Schubert, and R. Krausse. 1999. Comparative in vitro activity of levofloxacin, other fluoroquinolones, doxycycline, and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis. J. Antimicrob. Chemother.43(Suppl. C):33-36.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.32.10.1500"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.6.1181"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2571"},{"key":"e_1_3_2_27_2","unstructured":"Waites K. B. C. M. B\u00e9b\u00e9ar J. A. Robertson D. F. Talkington and G. E. Kenny. 2001. Cumitech 34 Laboratory diagnosis of mycoplasmal infections. Coordinating ed. F. S. Nolte. American Society for Microbiology Washington D.C."},{"key":"e_1_3_2_28_2","unstructured":"Waites K. B. and D. Taylor-Robinson. 1999. Mycoplasma and Ureaplasma p. 782-794. In P. R. Murray E. J. Baron M. A. Pfaller F. C. Tenover and R. H. Yolken (ed.) Manual of clinical microbiology 7th ed. American Society for Microbiology Washington D.C."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.1.161-165.2003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.47.1.161-165.2003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:57:24Z","timestamp":1645466244000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.47.1.161-165.2003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1128\/AAC.47.1.161-165.2003"],"URL":"https:\/\/doi.org\/10.1128\/aac.47.1.161-165.2003","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1]]},"assertion":[{"value":"2002-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-10-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2003-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}